美国安进地舒单抗注射液怎么购买?多少钱

How to buy Amgen injection in the United States? How much does it cost? Let us take a look below.

Desosumab is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. On May 27, 2019, Amgen China announced that denosumab has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and a body weight ≥45 kg).

In 2018, denosumab was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration. This approval makes denosumab the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

It is understood that a box of denosumab produced by Amgen in the United States is only about $1,500, and the price of the original drug on sale in China has dropped compared with the same period last year. Patients can go to foreign hospitals for treatment and get the medicine directly from the pharmacy, but this method is more suitable for patients with better family conditions. Generally, family patients can choose a regular domestic medical service company, such as Medical Companion Travel, and the medicines are also shipped from foreign pharmacies and mailed directly to their homes.

Amgen Biopharmaceutical Company (Amgen) is the world's leading innovative biopharmaceutical R&D and production company and one of the largest biopharmaceutical companies in the world. The company was founded by scientist George B. It was co-founded in 1980 by Dr. Rathmann, Dr. Joseph Rubinfeld and other venture capitalists. It takes "drug innovation" as its core concept and attaches great importance to the accumulation of R&D capabilities. It has achieved major breakthroughs in the fields of human genome, tumor biology, neuroscience, hematology and other fields.

On May 23, 2018, the U.S. FDA approved a new indication for Amgen, allowing the drug to be used to treat glucocorticoid-induced osteoporosis (GIOP), suitable for male and female patients at high risk of fractures.

Recommended related hot articles: /newsDetail/91194.html